Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years

Diamant Thaçi*, Stefano Piaserico, Kristian Gaarn Du Jardin, Richard B. Warren

*Corresponding author for this work
Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology
Issue number4
Pages (from-to)e501-e504
Publication statusPublished - 04.2023

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)
  • Centers: Center for Research on Inflammation of the Skin (CRIS)

DFG Research Classification Scheme

  • 205-19 Dermatology

Cite this